CL2011002972A1 - Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras. - Google Patents

Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras.

Info

Publication number
CL2011002972A1
CL2011002972A1 CL2011002972A CL2011002972A CL2011002972A1 CL 2011002972 A1 CL2011002972 A1 CL 2011002972A1 CL 2011002972 A CL2011002972 A CL 2011002972A CL 2011002972 A CL2011002972 A CL 2011002972A CL 2011002972 A1 CL2011002972 A1 CL 2011002972A1
Authority
CL
Chile
Prior art keywords
disorders
lxr
atherosclerosis
alzheimer
modulators
Prior art date
Application number
CL2011002972A
Other languages
English (en)
Inventor
Brett B Stevens William C Jr Kick Ellen K Zhang Haiying Bollu Venkataiah Martin Richard Mohan Busch
Original Assignee
Bristol Myers Squibb Co
Exelixis Patent Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43223342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002972(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Exelixis Patent Co Llc filed Critical Bristol Myers Squibb Co
Publication of CL2011002972A1 publication Critical patent/CL2011002972A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DAN A CONOCER COMPUESTOS DERIVADOS DE IMIDAZOL, ISÓTOPOS O SALES FA RMACÉ UTICA MENTE ACEPTABLES, MODULADORES DE LA ACTIVIDAD DE LOS RECEPTORES X DEL HÍGADO (LXR); COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES COMO: ATEROSCLEROSIS, RESISTENCIA A LA INSULINA, ARTROSIS, ACCIDENTE CEREBROVASCULAR, HIPERGLUCEMIA, DISLIPIDEMIA, PSORIASIS, FORMACIÓN DE ARRUGAS EN LA PIEL RELACIONADAS CON EXPOSICIÓN A UY Y LA EDAD, DIABETES, CÁNCER, ENFERMEDAD DE ALZHEIMER, INFLAMACIÓN, TRASTORNOS INMUNOLÓGICOS, TRASTORNOS LIPÍDICOS, OBESIDAD, DEGENERACIÓN MACULAR, ESTADOS CARACTERIZADOS POR UNA FUNCIÓN DE BARRERA EPIDÉRMICA ALTERADA, ESTADOS DE PROLIFERACIÓN EN EXCESO O DIFERENCIACIÓN ALTERADA DE LA EPIDERMIS O MEMBRANA MUCOSA O TRASTORNOS CARDIOVASCULARES.        
CL2011002972A 2009-05-28 2011-11-24 Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras. CL2011002972A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18173609P 2009-05-28 2009-05-28

Publications (1)

Publication Number Publication Date
CL2011002972A1 true CL2011002972A1 (es) 2012-08-17

Family

ID=43223342

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002972A CL2011002972A1 (es) 2009-05-28 2011-11-24 Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras.

Country Status (31)

Country Link
US (4) US8618154B2 (es)
EP (1) EP2435410B1 (es)
JP (1) JP5625050B2 (es)
KR (1) KR101676704B1 (es)
CN (1) CN102648184B (es)
AR (1) AR078049A1 (es)
AU (1) AU2010254082B2 (es)
BR (1) BRPI1013259B8 (es)
CA (1) CA2761934C (es)
CL (1) CL2011002972A1 (es)
CO (1) CO6470826A2 (es)
CY (1) CY1119407T1 (es)
DK (1) DK2435410T3 (es)
EA (1) EA019960B1 (es)
ES (1) ES2620451T3 (es)
HR (1) HRP20170194T1 (es)
IL (1) IL216176A (es)
LT (1) LT2435410T (es)
MX (1) MX2011012559A (es)
MY (1) MY153958A (es)
NZ (1) NZ596330A (es)
PE (1) PE20120797A1 (es)
PL (1) PL2435410T3 (es)
PT (1) PT2435410T (es)
SG (1) SG176247A1 (es)
SI (1) SI2435410T1 (es)
SM (1) SMT201700253T1 (es)
TN (1) TN2011000585A1 (es)
TW (1) TWI488844B (es)
WO (1) WO2010138598A2 (es)
ZA (1) ZA201108181B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101676704B1 (ko) * 2009-05-28 2016-11-16 엑셀리시스 페이턴트 컴퍼니 엘엘씨 Ｌｘｒ 조절자
AR088728A1 (es) * 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
SG10201607345YA (en) 2012-03-02 2016-11-29 Ralexar Therapeutics Inc Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
AU2013302861A1 (en) 2012-08-13 2015-03-05 The Rockefeller University Treatment and diagnosis of melanoma
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
CN105209039B (zh) * 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂
RS60479B1 (sr) 2013-09-04 2020-08-31 Ellora Therapeutics Inc Modulatori receptora x jetre (lxr)
JP2016532713A (ja) 2013-09-04 2016-10-20 アレクサー セラピューティクス， インク． 肝臓ｘ受容体（ｌｘｒ）調節因子
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
KR101815734B1 (ko) 2015-05-29 2018-01-05 가톨릭대학교 산학협력단 ｍｉＲ－７, ｍｉＲ－１８ａ 또는 ｍｉＲ－１８ｂ를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물
EP3402477A4 (en) 2016-01-11 2019-08-21 The Rockefeller University METHOD FOR THE TREATMENT OF DISEASES RELATED TO MYELOID-DERIVED SUPPRESSOR CELLS
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
EP3999055A1 (en) 2019-07-15 2022-05-25 Novartis AG Methods for treating meibomian gland dysfunction with liver x receptor agonists
CN110305141B (zh) * 2019-07-18 2022-01-11 深圳市三启药物开发有限公司 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途
CN115656401B (zh) * 2022-11-09 2025-03-28 武汉海特生物创新医药研究有限公司 一种咪唑-4-甲酸乙酯纯度的hplc检测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
CA2115452A1 (en) 1991-09-17 1993-04-01 Ronald M. Evans Receptor of the thyroid/steroid hormone receptor superfamily
CN1248916A (zh) 1997-01-24 2000-03-29 加利福尼亚大学董事会 FXR、PPARα和LXRα激活剂恢复屏障功能、促进表皮分化和抑制增生的用途
EP1115853A2 (en) 1998-09-23 2001-07-18 Ludmila Solomin Analysis of ligand activated nuclear receptors in vivo
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
EP1165135B1 (en) 1999-03-26 2004-09-01 City of Hope Methods of screening for compounds modulating fxr receptors
CN100513570C (zh) 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
WO2001082917A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
US7109227B2 (en) * 2002-08-26 2006-09-19 National Health Research Institutes Imidazolamino compounds
MXPA05012679A (es) * 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
CA2545942C (en) * 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
AU2005211809B2 (en) * 2004-02-11 2009-02-12 Irm Llc Compounds and compositions as LXR modulators
BRPI0612287A8 (pt) * 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
SG162803A1 (en) * 2005-06-27 2010-07-29 Exelixis Inc Imidazole based lxr modulators
KR20090094125A (ko) * 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
KR101676704B1 (ko) * 2009-05-28 2016-11-16 엑셀리시스 페이턴트 컴퍼니 엘엘씨 Ｌｘｒ 조절자

Also Published As

Publication number Publication date
EA019960B1 (ru) 2014-07-30
JP5625050B2 (ja) 2014-11-12
CO6470826A2 (es) 2012-06-29
TWI488844B (zh) 2015-06-21
AU2010254082B2 (en) 2015-01-29
CY1119407T1 (el) 2018-03-07
BRPI1013259B8 (pt) 2021-05-25
US8618154B2 (en) 2013-12-31
HRP20170194T1 (hr) 2017-05-19
DK2435410T3 (da) 2017-04-10
ZA201108181B (en) 2013-01-30
JP2012528180A (ja) 2012-11-12
TW201109308A (en) 2011-03-16
BRPI1013259B1 (pt) 2021-04-13
CN102648184A (zh) 2012-08-22
CA2761934C (en) 2018-01-09
MX2011012559A (es) 2012-06-08
KR20120047868A (ko) 2012-05-14
IL216176A (en) 2015-10-29
EP2435410B1 (en) 2017-01-18
AU2010254082A1 (en) 2011-12-08
NZ596330A (en) 2013-07-26
PE20120797A1 (es) 2012-07-08
SG176247A1 (en) 2012-01-30
EP2435410A2 (en) 2012-04-04
KR101676704B1 (ko) 2016-11-16
TN2011000585A1 (en) 2013-05-24
EA201171488A1 (ru) 2012-07-30
PL2435410T3 (pl) 2017-07-31
SMT201700253T1 (it) 2017-07-18
US20160280661A1 (en) 2016-09-29
MY153958A (en) 2015-04-30
US20120071534A1 (en) 2012-03-22
IL216176A0 (en) 2012-01-31
ES2620451T3 (es) 2017-06-28
WO2010138598A2 (en) 2010-12-02
LT2435410T (lt) 2017-04-10
SI2435410T1 (sl) 2017-06-30
CN102648184B (zh) 2015-09-30
BRPI1013259A2 (pt) 2016-04-05
PT2435410T (pt) 2017-05-03
US20150299136A1 (en) 2015-10-22
US20140163081A1 (en) 2014-06-12
AR078049A1 (es) 2011-10-12
WO2010138598A3 (en) 2011-07-28
CA2761934A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
CL2011002972A1 (es) Compuestos derivados de imidazol sustituido, moduladores de la actividad de receptores x del higado (lxr); composicion farmaceutica, utiles en el tratamiento de trastornos como aterosclerosis, resistencia a la insulina, artrosis, diabetes, enfermedad de alzheimer, entre otras.
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
PA8660801A1 (es) Anticuerpos antiamiloides humanizados
BR112012013431A8 (pt) composto, composição farmacêutica e seu uso
CR11854A (es) Compuestos de piridina
ES2657686T3 (es) Composición para aplicaciones cosméticas, farmacéuticas o dietéticas
BR112014026952A8 (pt) derivados de aminopirimidina pirazol, seus usos, e composição
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
CO2017003070A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
AR091000A1 (es) Polipeptidos de union a receptores de quimiocinas
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
AR083784A1 (es) Polipeptidos de enlace de los receptores de quimiocina
GT200600297A (es) Nuevos anticuerpos anti-madcam
ECSP055699A (es) Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
CL2015000717A1 (es) Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.
CL2008002506A1 (es) Compuestos derivados de bencimidazol sustituido, procedimiento de preparacion, composicion farmaceutica, util en el tratamiento de enfermedades moduladas con antagonistas del receptor fxr, en particular para el tratamiento de los niveles incrementados de lipidos y/o colesterol, enfermedad aterosclerotica, diabetes, cancer, parkinson, alzheimer.
UY32944A (es) Compuestos poliméricos de ésteres silil benzoicos, sus usos y composiciones
CL2011002467A1 (es) Compuestos derivados de 6-(3-aza-biciclo[3.1.0]hex-3-il)-2-fenilpirimidinas, antagonistas del receptor p2y 12; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos oclusivos. pct fase nacional.
UY31645A1 (es) Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso.